News

Patients treated every other month with the drug also showed a similar decrease in the rate of GA progression compared with sham treatment.

According to the study, pegcetacoplan injection reduced nonsubfoveal GA lesion growth by over 40% (monthly) in Year 3 compared to projected sham in the GALE extension study.

A new study focuses on the specific visual field conditions and defects that can result in an increased risk of vehicular accidents, particularly in the aging population.

Peter K. Kaiser, MD, highlights approaches in development for patients with dry age-related macular degeneration that have the potential not only to prevent vision loss but also to improve visual acuity.

Kodiak paused further development of tarcocimab last summer after its GLEAM and GLIMMER studies in diabetic macular edema did not meet their primary endpoint.

Ophthalmology experiences lower burnout rates than other medical specialties, but some may consider the exploration of alternative paths to maintain their professional fulfillment, explains Peter J. McDonnell, MD.

The company announced updated data from the OPTIC extension study of patients diagnosed with wet AMD during the Retina Subspecialty Day at the American Academy of Ophthalmology 2023 Annual Meeting in San Francisco.

Mary Elizabeth Hartnett, MD, FACS, discussed the impact of blindness and vision loss on women in the United States.

Kerrie Brady, president and chief executive officer of OcuTerra Therapeutics, shares progress in their Phase 2 DR:EAM Diabetic Retinopathy study, with promising results expected in Q1 2024 for their innovative eye drop treatment, OTT166.

Researchers are addressing growing concern over vision loss in people taking semaglutideat the American Academy of Ophthalmology annual meeting in San Francisco.

The latest innovations are in focus at the 127th annual meeting of the American Academy of Ophthalmology, being held at the Moscone Center in San Francisco.

Launched in 2014, Intelligent Research in Sight is the nation's first and largest comprehensive eye disease registry.

The collaboration, fueled by a $5 million donation from Knights Templar Eye Foundation (KTEF), will introduce a free and open VR simulation program for ophthalmologists and trainees worldwide.

Researchers found that spontaneous macular hole closure and surgical treatment seem to be associated with comparable rates of closure and visual outcomes.

The purpose of this investigation was 2-fold: to estimate the costs of treating GA with pegcetacoplan and to identify possible utility measures to compare treatments for GA.

OCT and OCTA imaging were especially valuable in this patient population because the images extended the current definition of sickle cell retinopathy.

Investigators have proposed a new algorithm, TWO-ROP, which they describe as “a new and simple screening protocol with a two-tiered impatient and outpatient approach.”

Researchers underscored the importance of ocular examinations in patients with primary vasculitis, defined as without an apparent cause.

Identifying and surmounting gender barriers in ophthalmology.

The company’s AI CLAIR technology platform has received FDA breakthrough device status, and if cleared by the FDA will deliver real-time cardiovascular disease risk assessments through routine eye exams.

The clinical trial will evaluate the safety and efficacy of CLS-AX (axitinib injectable suspension), a tyrosine kinase inhibitor. According to the company, topline data is expected during the third quarter of 2024.

Innovative new features build on the benefits of the iCare COMPASS Automated Perimeter

Prevent Blindness is offering videos, fact sheets, social media graphics and PowerPoint presentations to educate the public on the potential effects diabetes may have on vision.

The collection at the Truhlsen-Marmor Museum of the Eye includes more than 38,000 objects, including rare books, instruments and immersive educational materials.

Researchers have delved into the possibility of cell-based therapy in ophthalmology. By targeting vitreoretinal diseases, they are tackling a range of vision-threatening disorders which often result in severe irreversible vision loss.

According to Genentech, RVO is the third indication for Vabysmo, in addition to wet, or neovascular, age-related macular degeneration and diabetic macular edema. The approval is based on two Phase III studies demonstrating early and sustained vision improvements that were non-inferior to aflibercept.

The issuance provides patent protection in the U.S. for therapeutics incorporating the optimized ELOVL2 transgene until 2041. The patent is being prosecuted in the European Union and other countries around the globe. The company said the patent adds value to its lead program in dry AMD.

According to the company, the software is designed to streamline the flow of information, surgical planning, and enable electronic medical record and diagnostic device integration.